Eliza Yankova

Eliza Yankova

Auto-generated profile, based on publicly available information

Eliza Yankova

Cambridge Stem Cell Institute, University of Cambridge, Cambridge, UK

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 April 2021 in Nature
Verified
Journal Article
Closed access
PDF file
EYEliza Yankova
Eliza Yankova
WBWesley Blackaby
Wesley Blackaby
MAMark Albertella
Mark Albertella
JRJustyna Rak
Justyna Rak
EBEtienne De Braekeleer
Etienne De Braekeleer
TKTony Kouzarides
Tony Kouzarides

16 April 2025 in Nature
Verified
Journal Article
Open access
PDF file
MGMalgorzata Gozdecka
Malgorzata Gozdecka
MDMonika Dudek
Monika Dudek
SWSean Wen
Sean Wen
MGMuxin Gu
Muxin Gu
RSRichard J. Stopforth
Richard J. Stopforth
GVGeorge S. Vassiliou
George S. Vassiliou
Somatic DNMT3A-R882 codon mutations drive the most common form of clonal haematopoiesis (CH) and are associated with increased acute myeloid leukaemia (AML) risk1,2. Preventing expansion of DNMT3A-R882-mutant haematopoietic stem/progenitor cells (HSPCs) may therefore avert progression to AML. To identify DNMT3A-R882-mutant-specific vulnerabilities, we conducted a genome-wide CRISPR screen on primary mouse Dnmt3a R882H/+ HSPCs. Among the 640 vulnerability genes identified, many were involved in mitochondrial metabolism, and metabolic flux analysis confirmed enhanced oxidative phosphorylation use in Dnmt3a R882H/+ versus Dnmt3a +/+ (WT) HSPCs. We selected citrate/malate transporter Slc25a1 and complex I component Ndufb11, for which pharmacological inhibitors are available, for downstream studies. In vivo administration of SLC25A1 inhibitor CTPI2 and complex I inhibitors IACS-010759 and metformin suppressed post-transplantation clonal expansion of Dnmt3a R882H/+, but not WT, long-term haematopoietic stem cells. The effect of metformin was recapitulated using a primary human DNMT3A-R882 CH sample. Notably, analysis of 412,234 UK Biobank participants showed that individuals taking metformin had a markedly lower prevalence of DNMT3A-R882-mutant CH, after controlling for potential confounders including glycated haemoglobin, diabetes and body mass index. Collectively, our data propose modulation of mitochondrial metabolism as a therapeutic strategy for prevention of DNMT3A-R882-mutant AML.

2 July 2021 in Science Advances
Verified
Journal Article
Open access
PDF file
NHNamshik Han
Namshik Han
WHWoochang Hwang
Woochang Hwang
KTKonstantinos Tzelepis
Konstantinos Tzelepis
PSPatrick Schmerer
Patrick Schmerer
EYEliza Yankova
Eliza Yankova
TKTony Kouzarides
Tony Kouzarides
Data-driven computational analysis and simulation identified drug repurposing opportunities for COVID-19.

24 August 2016 in Scientific Reports
Verified
Journal Article
Open access
PDF file
EBEmma Barnard
Emma Barnard
JLJared Liu
Jared Liu
EYEliza Yankova
Eliza Yankova
SCSilvana M. Cavalcanti
Silvana M. Cavalcanti
MMMarcelo Magalhães
Marcelo Magalhães
Andrew McdowellAndrew Mcdowell
Andrew Mcdowell
Progressive macular hypomelanosis (PMH) is a common skin disorder that causes hypopigmentation in a variety of skin types. Although the underlying aetiology of this condition is unclear, there is circumstantial evidence that links the skin bacteriumPropionibacterium acnesto the condition. We now describe the first detailed population genetic analysis ofP. acnesisolates recovered from paired lesional and non-lesional skin of PMH patients. Our results demonstrate a strong statistical association between strains from the type III phylogenetic lineage and PMH lesions (P = 0.0019), but not those representing other phylogroups, including those associated with acne (type IA1). We also demonstrate, based onin silico16S rDNA analysis, that PMH isolates previously recovered from patients in Europe are also consistent with the type III lineage. Using comparative genome analysis, we identified multiple genomic regions that are specific for, or absent from, type III strains compared to other phylogroups. In the former case, these include open reading frames with putative functions in metabolism, transport and transcriptional regulation, as well as predicted proteins of unknown function. Further study of these genomic elements, along with transcriptional and functional analyses, may help to explain why type III strains are associated with PMH.

23 April 2025 in Nature Biotechnology
Verified
Journal Article
Open access
PDF file
BGBenson M. George
Benson M. George
MEMaria Eleftheriou
Maria Eleftheriou
EYEliza Yankova
Eliza Yankova
JPJonathan Perr
Jonathan Perr
PCPeiyuan Chai
Peiyuan Chai
KTKonstantinos Tzelepis
Konstantinos Tzelepis
Immunotherapies for acute myeloid leukemia (AML) and other cancers are limited by a lack of tumor-specific targets. Here we discover that RNA-binding proteins and glycosylated RNAs (glycoRNAs) form precisely organized nanodomains on cancer cell surfaces. We characterize nucleophosmin (NPM1) as an abundant cell surface protein (csNPM1) on a variety of tumor types. With a focus on AML, we observe csNPM1 on blasts and leukemic stem cells but not on normal hematopoietic stem cells. We develop a monoclonal antibody to target csNPM1, which exhibits robust anti-tumor activity in multiple syngeneic and xenograft models of AML, including patient-derived xenografts, without observable toxicity. We find that csNPM1 is expressed in a mutation-agnostic manner on primary AML cells and may therefore offer a general strategy for detecting and treating AML. Surface profiling and in vivo work also demonstrate csNPM1 as a target on solid tumors. Our data suggest that csNPM1 and its neighboring glycoRNA–cell surface RNA-binding protein (csRBP) clusters may serve as an alternative antigen class for therapeutic targeting or cell identification.

28 January 2026 in Nature
Verified
Journal Article
Open access
PDF file
PCPeiyuan Chai
Peiyuan Chai
SKSina Kheiri
Sina Kheiri
AKAndrew Kuo
Andrew Kuo
JSJessica Shah
Jessica Shah
LKLauren Kageler
Lauren Kageler
RFRyan A. Flynn
Ryan A. Flynn
Heparan sulfate proteoglycans (HSPGs) have been recognized as key plasma membrane-tethered co-receptors for a broad range of growth factors and cytokines containing cationic heparan-binding domains1,2. However, how HSPGs mechanistically mediate signalling at the cell surface—particularly in the context of cell surface RNA—remain poorly understood. During developmental and disease processes, vascular endothelial growth factor (VEGF-A), a heparan sulfate-binding factor, regulates endothelial cell growth and angiogenesis3. The regulatory paradigm for endothelial cell-mediated selectively of VEGF-A binding and activity has largely been focused on understanding the selective sulfation of the anionic heparan sulfate chains4,5,6,7,8. Here we examine the organizational rules of a new class of anionic cell surface conjugates, glycoRNAs9,10, and cell surface RNA-binding proteins (csRBPs11,12). Leveraging genome-scale knockout screens, we discovered that heparan sulfate biosynthesis and specifically the 6-O-sulfated forms of heparan sulfate chains are critical for the assembly of clusters of glycoRNAs and csRBPs (cell surface ribonucleoproteins (csRNPs)). Mechanistically, we show that these clusters antagonize heparan sulfate-mediated activation of ERK signalling downstream of VEGF-A. We demonstrate that the heparan sulfate-binding domain of VEGF-A165 is responsible for binding RNA, and that disrupting this interaction enhances ERK signalling and impairs vascular development both in vitro and in vivo and is conserved across species. Our study thus uncovers a previously unrecognized regulatory axis by which csRNPs negatively modulate heparan sulfate-mediated signalling in the context of angiogenesis driven by VEGF-A.